Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T and TCR Programs at the 58th American Society of Hematology Annual Meeting
Five abstracts accepted, including oral presentation on BPX-501
Investor / analyst luncheon event on BPX-501 to be held
Investor/Analyst Luncheon
Bellicum will host an investor and analyst luncheon on
ASH Presentations on Bellicum Programs
BPX-501:
Oral Presentation: “Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (Inducible Caspase 9, iC9) After T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (Haplo-HSCT)”
Abstract Number: 72
Session Name: 732.Clinical
Allogeneic Transplantation: Results: Predicting Outcome
Date:
Session Time:
Presentation Time:
Poster Presentation: “T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (Haplo-HSCT) Followed by Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies”
Abstract Number: 4683
Session Name: 732.Clinical
Allogeneic Transplantation: Results: Poster III
Date:
Presentation Time:
Poster Presentation: “Clinical Outcome and Immune Recovery after Adoptive Infusion of BPX-501 Cells (Donor T Cells Transduced with iC9 Suicide Gene) in Children with Hemoglobinopathies and Diamond-Blackfan Anemia Given a/b T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (HSCT)”
Abstract Number: 2286
Session Name: 732.Clinical
Allogeneic Transplantation: Results: Poster I
Date:
Presentation Time:
CAR-T Program: (CD123 CARs)
Poster Presentation: “Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication by CD123-Specific Chimeric Antigen Receptor T Cells”
Abstract Number: 4551
Session Name: 703.Adoptive
Immunotherapy: Poster III
Date:
Presentation
Time:
TCR Program: (PRAME and Bob-1 TCRs)
Poster Presentation: “Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma”
Abstract Number: 4550
Session Name: 703.Adoptive
Immunotherapy: Poster III
Date:
Presentation
Time:
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161103005919/en/
Source:
Bellicum Pharmaceuticals
Investors:
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
or
BMC
Communications
Media:
Brad Miles, 646-513-3125
bmiles@bmccommunications.com